We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

CYDY CytoDyn Inc (QB)

-0.055 (-21.36%)
Mar 01 2024 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 8,236,298
Bid Price 0.1955
Ask Price 0.205
News (2)
Day High 0.27


52 Week Range


Day Low 0.1975
Share Name Share Symbol Market Stock Type
CytoDyn Inc (QB) CYDY OTCMarkets Common Stock
  Price Change Price Change % Share Price Last Trade
-0.055 -21.36% 0.2025 15:00:05
Open Price Low Price High Price Close Price Previous Close
0.2621 0.1975 0.27 0.2025 0.2575
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
1,062 8,236,298 US$ 0.224773 US$ 1,851,294 - 0.1456 - 0.48
Last Trade Type Quantity Price Currency
15:02:09 formt 17,361 US$ 0.205 USD

CytoDyn Inc (QB) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
195.91M 921.12M 556.02M 0 -79.82M -0.08 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

CytoDyn (QB) News

Date Time Source News Article
3/01/202416:16Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]
3/01/202416:15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]
2/22/202416:16Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]
2/21/202423:15Edgar (US Regulatory)Form EFFECT - Notice of Effectiveness
2/15/202420:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of..
2/12/202416:31Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial..
1/29/202416:22Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]
1/29/202407:40Edgar (US Regulatory)Form 8-K - Current report
1/19/202416:15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]
1/16/202416:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
1/05/202420:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
1/05/202420:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No CYDY Message Board. Create One! See More Posts on CYDY Message Board See More Message Board Posts

Historical CYDY Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.16480.270.15750.21509925,468,1020.037722.88%
1 Month0.18180.270.1550.18856583,165,4580.020711.39%
3 Months0.23010.35950.15050.20017313,493,840-0.0276-11.99%
6 Months0.210.4180.14560.19756722,362,548-0.0075-3.57%
1 Year0.320.480.14560.22901541,942,286-0.1175-36.72%
3 Years4.515.050.14560.94965992,339,890-4.31-95.51%
5 Years0.5310.010.14562.202,831,139-0.3275-61.79%

CytoDyn (QB) Description

CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes. CytoDyn is studying leronlimab in multiple therapeutic areas, including infectious disease, cancer, and autoimmune conditions.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |